Literature DB >> 21099665

Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline.

Norma I Rallon1, Clara Restrepo, Susanna Naggie, Mariola Lopez, Jorge Del Romero, David Goldstein, John McHutchison, Vincent Soriano, Jose M Benito.   

Abstract

The critical role of interleukin-28B (IL28B)/interferon-λ3 (IFN-λ3) polymorphisms on the susceptibility to hepatitis C virus infection and the response to peginterferon-ribavirin therapy has encouraged exploration of similar effects on other viruses. Given that IFN-λ mediates anti-HIV-1 activity, the protective role of IL28B polymorphisms was examined in 29 seronegative individuals at risk for HIV-infection and in 68 HIV-positive carriers with and without rapid progression of immunodeficiency. No protective role of IL28B polymorphism was found examining both HIV-disease progression and HIV-protection.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21099665     DOI： 10.1097/QAD.0b013e328341b84e

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  12 in total

1.  Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis.

Authors:  Chrissa G Tsiara; Georgios K Nikolopoulos; Niki L Dimou; Katerina G Pantavou; Pantelis G Bagos; Benedicta Mensah; Michael Talias; Georgia G Braliou; Dimitra Paraskeva; Stefanos Bonovas; Angelos Hatzakis
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

Review 2.  A new standard of care for the treatment of chronic HCV infection.

Authors:  Wolf Peter Hofmann; Stefan Zeuzem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-05       Impact factor: 46.802

3.  Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs.

Authors:  Ene-Ly Jõgeda; Radko Avi; Merit Pauskar; Eveli Kallas; Tõnis Karki; Don Des Jarlais; Anneli Uusküla; Karolin Toompere; Irja Lutsar; Kristi Huik
Journal:  J Med Virol       Date:  2018-08-16       Impact factor: 2.327

4.  The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.

Authors:  Zobair M Younossi; Aybike Birerdinc; Mike Estep; Maria Stepanova; Arian Afendy; Ancha Baranova
Journal:  J Transl Med       Date:  2012-02-07       Impact factor: 5.531

Review 5.  Innate immunity: a new chapter for hepatitis C.

Authors:  Theresa Hydes; Salim I Khakoo
Journal:  Ann Gastroenterol       Date:  2012

6.  HIV-1 Promoter Single Nucleotide Polymorphisms Are Associated with Clinical Disease Severity.

Authors:  Michael R Nonnemacher; Vanessa Pirrone; Rui Feng; Brian Moldover; Shendra Passic; Benjamas Aiamkitsumrit; Will Dampier; Adam Wojno; Evelyn Kilareski; Brandon Blakey; Tse-Sheun Jade Ku; Sonia Shah; Neil T Sullivan; Jeffrey M Jacobson; Brian Wigdahl
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 7.  Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.

Authors:  S Chinnaswamy
Journal:  Genes Immun       Date:  2016-06-09       Impact factor: 2.676

8.  Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis.

Authors:  Carolina Scagnolari; Fabio Midulla; Elisabetta Riva; Katia Monteleone; Angelo Solimini; Enea Bonci; Giulia Cangiano; Paola Papoff; Corrado Moretti; Alessandra Pierangeli; Guido Antonelli
Journal:  Virus Res       Date:  2012-02-25       Impact factor: 3.303

Review 9.  Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome.

Authors:  Carolina Scagnolari; Guido Antonelli
Journal:  Cytokine Growth Factor Rev       Date:  2018-03-16       Impact factor: 7.638

10.  Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load.

Authors:  Sabri Saeed Sanabani; Youko Nukui; Juliana Pereira; Antonio Charlys da Costa; Ana Carolina Soares de Oliveira; Rodrigo Pessôa; Fabio Eudes Leal; Aluisio C Segurado; Esper Georges Kallas; Ester Cerdeira Sabino
Journal:  BMC Infect Dis       Date:  2012-12-23       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.